Business Context and Reporting Period
This Form 8-K is filed by Hemispherx Biopharma, Inc. (not AIM Immunotech Inc.) on March 2, 2018, reporting an event that occurred on February 27, 2018. The company is a Delaware corporation headquartered in Orlando, Florida.
Key Financial Metrics
The filing reports a specific transaction involving the sale of a wholly owned property located at 5 Jules Lane, New Brunswick, New Jersey. The purchase price for this asset was $1,050,000. The filing text does not provide clear values for overall revenue, profit, cash flow, margins, debt, or liquidity positions for the reporting period.
Material Changes
The material change reported is the divestiture of an unencumbered, unutilized property. The sale was executed pursuant to a sale agreement dated September 11, 2017, with the transaction closing on February 27, 2018.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the disclosure of the asset sale. No unusual items or contingencies are detailed in this report.
Investor Verification Checklist
- Verify the final closing date and receipt of the $1,050,000 purchase price.
- Confirm the accounting treatment of the sale proceeds (e.g., gain/loss recognition) in the next quarterly report.
- Review the company's current cash position to assess the impact of this liquidity event.
- Check for any remaining obligations or liabilities associated with the property at 5 Jules Lane.